Clinical efficacy assessments: data are mean scores (percentage change from baseline).
| Endpoint* | Baseline | Week 60 | Week 108 | |||
|---|---|---|---|---|---|---|
| PBO/ETN, n = 39 | ETN/ETN, n = 42 | PBO/ETN, n = 39 | ETN/ETN, n = 42 | PBO/ETN, n = 39 | ETN/ETN, n = 42 | |
| BASDAI, mm | 58.6 | 60.9 | 27.0 (53.9) | 21.3 (65.1) | 29.1 (50.3) | 23.0 (62.3) |
| PtGA, mm | 63.4 | 66.2 | 29.8 (53.0) | 23.0 (65.3) | 28.8 (54.5) | 21.9 (67.0) |
| Total back pain, mm | 56.5 | 62.2 | 27.3 (51.7) | 18.7 (70.0) | 29.9 (47.1) | 22.5 (63.9) |
| Nocturnal back pain, mm | 55.8 | 59.1 | 21.7 (61.0) | 15.0 (74.6) | 25.2 (54.9) | 17.2 (70.9) |
| BASFI, mm | 57.2 | 60.1 | 33.7 (41.1) | 29.3 (51.3) | 34.6 (39.6) | 30.4 (49.4) |
| Morning stiffness, mm | 62.9 | 67.9 | 25.7 (59.1) | 25.5 (62.4) | 27.9 (55.6) | 25.3 (62.7) |
↵* Assessed on VAS 0–100 mm scale. BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; ETN: etanercept; PBO: placebo; PtGA: patient global assessment; VAS: visual analog scale.